- Home
- PETS vs VNRX Comparison
PETS vs VNRX Comparison
Compare PETS & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | VNRX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 38.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PETS | VNRX |
|---|---|---|
| Price | $3.01 | $0.27 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $3.20 | $3.17 |
| AVG Volume (30 Days) | ★ 6.9M | 2.8M |
| Earning Date | 02-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,972,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | $2.98 | $493.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.48 |
| 52 Week Low | $1.57 | $0.27 |
| 52 Week High | $6.08 | $0.94 |
Technical Indicators
Market Signals| Indicator | PETS | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.48 | 31.94 |
| Support Level | $1.69 | $0.28 |
| Resistance Level | $4.05 | $0.31 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 55.24 | 3.40 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.